Cytek Biosciences Appoints New Director, Reports Officer Compensation
Ticker: CTKB · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1831915
| Field | Detail |
|---|---|
| Company | Cytek Biosciences, Inc. (CTKB) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $420,000, $1,250,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, executive-compensation, governance
Related Tickers: CTK
TL;DR
Cytek just swapped a director and is talking about exec pay. Board changes incoming.
AI Summary
Cytek Biosciences, Inc. announced on March 17, 2024, the departure of Director Dr. Robert J. Massoud and the appointment of Dr. David J. Ebersole as a new director. The company also reported on compensatory arrangements for certain officers. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine board changes and compensation disclosures, with no immediate financial distress or significant operational shifts indicated.
Key Players & Entities
- Cytek Biosciences, Inc. (company) — Registrant
- Dr. Robert J. Massoud (person) — Departing Director
- Dr. David J. Ebersole (person) — Appointed Director
- March 17, 2024 (date) — Date of earliest event reported
FAQ
Who is Dr. David J. Ebersole and what is his background?
The filing does not provide specific details about Dr. David J. Ebersole's background or qualifications beyond his appointment as a director.
What were the reasons for Dr. Robert J. Massoud's departure?
The filing states Dr. Robert J. Massoud's departure as a director but does not provide specific reasons for his departure.
What specific compensatory arrangements for certain officers are being reported?
The filing indicates that compensatory arrangements of certain officers are being reported, but the specific details of these arrangements are not elaborated upon in the provided text.
Is this filing related to any financial performance updates for Cytek Biosciences?
This filing is a current report (8-K) primarily detailing the departure of a director, election of a new director, and compensatory arrangements. It does not appear to contain financial statements or performance updates.
What is the significance of the 'FORM 8-K' filing?
A Form 8-K is a report of unscheduled material events or corporate changes that could be of importance to investors.
Filing Stats: 1,086 words · 4 min read · ~4 pages · Grade level 10.3 · Accepted 2024-03-19 17:00:01
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CTKB Nasdaq Global Select
- $420,000 — providing for an annual base salary of $420,000 and eligibility to participate in the C
- $1,250,000 — receive equity grants in the amount of $1,250,000, comprised of 50% in stock options and
Filing Documents
- d773908d8k.htm (8-K) — 30KB
- d773908dex101.htm (EX-10.1) — 21KB
- d773908dex991.htm (EX-99.1) — 14KB
- g773908g0319145259593.jpg (GRAPHIC) — 2KB
- g773908g0319145259699.jpg (GRAPHIC) — 2KB
- g773908g0319165234809.jpg (GRAPHIC) — 3KB
- g773908g0319165235140.jpg (GRAPHIC) — 7KB
- 0001193125-24-071467.txt ( ) — 215KB
- ctkb-20240317.xsd (EX-101.SCH) — 3KB
- ctkb-20240317_lab.xml (EX-101.LAB) — 17KB
- ctkb-20240317_pre.xml (EX-101.PRE) — 11KB
- d773908d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Offer Letter between William McCombe and the Company dated February 22, 2024, as amended by the Amendment dated March 18, 2024. 99.1 Press Release dated March 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cytek Biosciences, Inc. Date: March 19, 2024 By: /s/ Wenbin Jiang, Ph.D. Wenbin Jiang, Ph.D. President and Chief Executive Officer